🇺🇸

US SEC Filing Intelligence

Daily AI-powered analysis of SEC EDGAR filings, FDA approvals, and US regulatory disclosures. Investment signals, risk flags, and sector themes for US markets.

·daily

US Earnings Financial Results SEC Filings — April 08, 2026

Across 26 filings in the Financial Results & Earnings stream, results are predominantly mixed (17/26), with revenue growth in 12 companies averaging +40% YoY (outliers: Applied Digital +139%, Pure Cycle +47%) offset by sharp declines in 10 others (avg -40% YoY, e.g., Nurix -66%, Aehr -44%). Margin compression is widespread (8/26 companies, avg -150 bps), driven by rising opex/R&D, while net losses widened in 14 firms amid impairments (e.g., Beasley $225M FCC licenses) and cash burn (15/26 cash declines, avg -50%). Positive net income in 6 companies (e.g., Grown Rogue turnaround to $3.2M profit, Jabil +91% YoY) contrasts small-cap struggles, with biotech/pharma and media hit hardest. Capital allocation favors buybacks/dividends in performers (e.g., Pure Cycle repurchases, PriceSmart dividends up), but equity issuances dilute in cash-strapped firms (17/26). Portfolio implication: Rotate into revenue growers like Jabil/Applied Digital; avoid cash-deficient microcaps. Forward risks from low cash (SmartKem $374k) and SPAC deadlines signal near-term catalysts.

26 high priority26 total filings
·daily

US Earnings Financial Results SEC Filings — April 07, 2026

Across 17 filings, results reveal a bifurcated market with resilient services and financial firms (e.g., Cintas +8.9% YoY revenue, Jefferies +16.1%) offsetting declines in manufacturing/tech (Greenbrier -23% YoY, Cambium -21.8%) and biotechs (Jaguar Health losses widening 37.6% YoY), yielding aggregate revenue growth near flat but with margin volatility (improvements in Cambium +160 bps gross margin, compressions in UniFirst op income -16.7%). Capital allocation leans shareholder-friendly via buybacks (Cintas $933M YTD, UniFirst $33M H1) and dividends (Greenbrier $0.64/share, Phoenix $0.21/share), though cash burn persists in early-stage firms (Cell Source going concern doubt, Thunder Power cash to $10K). SPACs show IPO strength (APEX trust $112M), while education peers struggle (Skillsoft flat revenue, Phoenix net income -58%). Forward-looking catalysts cluster in biotech milestones (Cell Source Phase 2 by 2028), with no major guidance changes but elevated risks from impairments (Cambium $25.5M, Skillsoft 6.2% of rev). Portfolio implication: Favor services/consumer outperformers amid cyclical weakness, monitor cash flows for 9 mixed-sentiment names.

17 high priority17 total filings
·daily

US Earnings Financial Results SEC Filings — April 06, 2026

Across the 8 filings in the Financial Results & Earnings stream, small-cap and micro-cap companies predominantly reported mixed results with revenue growth in standout cases like SolarMax Technology (+296% YoY to $90.982M) and iQSTEL (+11.9% YoY to $316.9M), but widespread margin compression (e.g., SolarMax gross margin -550 bps to 4.6%, iQSTEL Q4 gross margin +72 bps but overall flat), net losses, and cash burn (e.g., STRATEGIC ACQUISITIONS -98% cash to $508, Nutra -90.1% to $3,603). Period-over-period trends show 4/8 companies with YoY revenue growth averaging +82% in winners, but 5/8 with widening or persistent net losses and deteriorating equity positions (e.g., Elvictor swung to -$175k loss, Neolara full asset impairment). Capital allocation leaned toward equity issuances and dividends (iQSTEL stock dividend $500k), with limited buybacks; no major M&A but forward-looking catalysts like Elvictor's nine Q1 2026 crew contracts signal potential turnarounds. Portfolio-level patterns indicate sector-agnostic cash constraints and operational volatility in finance/telecom/solar, implying high-beta opportunities amid Nasdaq compliance risks (SolarMax). Overall materiality skews high (avg 7.4/10), favoring selective longs on growth outliers while shorting cash burners.

8 high priority8 total filings
·daily

US Earnings Financial Results SEC Filings — April 03, 2026

Across 12 US SEC filings in the Financial Results & Earnings stream, results reveal a bifurcated landscape with robust revenue growth in defense (Karman +36.6% YoY) and professional services (RCM +14.7% YoY, Concentrix +5.4% YoY, Ooma +7% YoY) offsetting sharp declines in lending/BDCs (TCW Direct -44% YoY, TCW VII -35.1% YoY), microcaps (Totaligent -99.5% YoY, Token -85% YoY), and others (POWERDYNE -7.2% YoY). Margin trends are mixed, with compression in 7/12 companies (e.g., Karman -2.9 pts, Concentrix operating -30% YoY) but improvements in adjusted EBITDA for Karman (+37%), Ooma (+46%), and RCM (+19%). Net losses narrowed in loss-making firms like GOOD GAMING (-75.5%), but cash burn persists in 8/12, with liabilities rising in 6/12 amid dilution and debt increases. Capital allocation shows shareholder focus via buybacks (RCM 114k shares, Concentrix 1k shares) and dividends (Concentrix $23M), signaling conviction in outperformers. Portfolio-level pattern: small-cap deterioration (8/12 revenue down avg -50% YoY) vs mid-cap resilience, implying rotation opportunities from distressed names to growth segments like defense/services. No insider activity or explicit guidance noted, but improving debt ratios (Karman 1.52 from 2.25) and backlog growth flag early recovery signals.

12 high priority12 total filings
·daily

US Earnings Financial Results SEC Filings — April 02, 2026

Across 19 US SEC filings for Q1/FY2025-2026 financial results, results are predominantly mixed (17/19), with revenue growth in 10 companies averaging +22% YoY (led by Navan +31%, Regional Health +190%, DYNA +26%), but declines in 7 averaging -20% YoY (Lindsay -16%, Lovesac other -37%); margins compressed in 7 firms by avg -150bps (Lovesac -210bps, Caleres -190bps, IRIDEX -460bps). Net income swings to profit in 5 (DYNA from -$8.5M to +$3.8M, Regional Health from -$3.2M to +$3.4M), while losses narrowed in 4 but widened in others; operating cash flow improved in 8/15 reported (FactSet +28%, Acuity +20%). Capital allocation favors buybacks ($303M FactSet, $103M Acuity, $80M TD SYNNEX, $56M Lindsay), signaling management conviction amid $1B+ total returns, though cash piles declined QoQ in 10/16 (TD SYNNEX -36%, Acuity -36%). Microcaps face acute risks (Algorhythm going concern, Vitaspring $3.5M deficit), SPACs (Iron Horse, Starry Sea) build trust accounts post-IPO, and medtech/retail show segment shifts (ChargePoint subscriptions +13% mix). Portfolio implication: Favor buyback-heavy mid/large caps (TD SYNNEX, FactSet) for stability, avoid cash-burn shells (Byrn, Vitaspring); sector rotation to distribution/mining growth.

19 high priority19 total filings
·daily

US Earnings Financial Results SEC Filings — March 31, 2026

Across 50 10-K filings for FY2025 (ended Dec 31, 2025), mixed sentiment dominates with 14/50 explicitly mixed, reflecting turnarounds in select operating companies (e.g., TruBridge net income from -$21M to +$4M, HireQuest +72% net income) amid widespread losses in biotechs/pharma (avg loss expansion +100% YoY in Athira, Sharps, OS Therapies). Revenue trends show resilience in retail (Ross Stores +8% YoY to $22.8B, FitLife +26%) but declines in resources (CKX Lands -45%, SD Soy -9%) and flatlines in tech/services (KORE 0%, TruBridge +1%); operational cash flow improved in 6/15 detailed cos (e.g., Ross +28% to $3B). CMBS trusts (16/50) uniformly neutral with recurring master servicer transitions to Trimont LLC effective Mar 1, 2025, signaling standardization but no delinquencies flagged. SPACs/funds (10/50) hold robust trust assets (e.g., Berto $309M, Invest Green $173M) with low materiality risks pre-combination. Biotech cash burn persists (OS Therapies cash -95% to $270k) offset by financings (Athira PIPE $82M net); capital allocation favors equity raises over dividends/buybacks. Portfolio implication: Favor retail turnaround plays, monitor CMBS servicer shifts for liquidity hints, avoid high-burn biotechs without catalysts.

50 high priority50 total filings
·daily

US Earnings Financial Results SEC Filings — March 30, 2026

Across 50 10-K and 10-Q filings from March 30, 2026, primarily small-cap biotechs, SPACs, crypto/AI firms, and financial trusts, sentiment is mixed (70% of filings), with 18 companies narrowing net losses YoY (avg improvement 40%, e.g., OneMedNet -72%, ImmuCell -52%) amid revenue volatility: 14 firms grew revenue (avg +95% YoY, outlier OneMedNet +111%), 13 declined (avg -18%, e.g., Soluna -22%, Origin -40%). Biotechs (12 filings) show R&D cuts in 6 but persistent cash burn (avg op cash use +15%), while SPACs (12) hold trust assets ($10B+ aggregate) but report deficits and no combinations. Crypto firms (5) post impairments ($40M+) offset by financing ($150M+ inflows). Capital allocation leans to financing raises ($1B+ aggregate) over dividends/buybacks; no insider trades noted, but 8 firms flag going concerns. Portfolio implications: Selective opportunities in turnarounds like Galaxy Gaming (profitability flip), risks in high-burn biotechs and pre-IPO SPACs; sector rotation toward profitable niches like banks (GBank NI +12%).

50 high priority50 total filings
·daily

US Earnings Financial Results SEC Filings — March 27, 2026

Across 50 10-K filings for FY ended Dec 31, 2025, a stark divide emerges: 30+ ABS trusts (Ally Auto, Exeter Auto, Navient/SLM Student Loan) confirm full servicing compliance with neutral sentiment and no material issues or metrics, signaling stability in securitized auto/student loan markets. Operating companies (20 filings) reveal volatile growth, with digital asset firms (BitGo +424% YoY revenue to $16.2B, FG Nexus +210% to $2.4M, American Bitcoin +159% to $185M) driving top-line surges but massive net losses from unrealized digital asset impairments (e.g., BitGo -$14.8M vs +$156K prior). SPACs/blank checks (OTG, Republic Digital, Galata II, Launch Two) hold steady trusts yielding interest income (e.g., Launch Two net income +302% YoY to $8.9M), while biotech/tech (Luminar -12% rev, Cyngn -40%, Phunware -20%) face revenue declines and cash burns amid narrowing losses in some (Instil Bio -4% loss improvement, Werewolf -14%). Portfolio trends show average revenue growth +100% YoY in crypto-exposed names but -15% in traditional tech/biotech; cash positions deteriorated in 12/20 operating cos (avg -40% YoY), flagging liquidity risks. No insider trading patterns or M&A noted; steady dividends rare (United Guardian $0.60/share). Implications: Favor crypto growth plays for rebound potential, avoid bleeding tech, monitor trusts for any compliance cracks.

50 high priority50 total filings
·daily

US Earnings Financial Results SEC Filings — March 25, 2026

Across 50 SEC filings for Q4 2025/FY2025 financial results, mixed sentiment dominates (35/50 filings), with tech/software firms like UiPath (+13% YoY revenue to $1.61B, profitability turnaround) and Pure Storage (+16% to $3.66B) showing revenue growth averaging 17% YoY but flat/declining margins due to opex rises (e.g., R&D +20% at Pure). SPACs (15+ filings) generated net income primarily from trust interest (e.g., Range Capital $4.0M), though redemptions depleted trusts (e.g., Concord 99.6% drop). Biotechs/pharma (10+) faced revenue cliffs (e.g., KIORA $0 vs $16M) and R&D-driven loss widening (avg +50% opex), narrowing losses in oil/gas (CoJax -31%) and select industrials. Portfolio trends: 12/20 operating cos with >10% revenue growth but 8/12 margin compression (-100bps avg); cash burn persists in 70% small caps. Critical implications: Favor tech profitability inflection (UiPath, Braze cash flow double), monitor SPAC liquidations post-redemptions, avoid biotech cash drains without catalysts. Capital allocation leans conservative (e.g., Chewy FCF +24% to $562M), with M&A sparse but accretive (Securetech AI UltraProd).

50 high priority50 total filings
·daily

US Earnings Financial Results SEC Filings — March 24, 2026

Across 50 filings dated March 24, 2026, primarily FY2025 10-Ks, sentiment is predominantly mixed (24/50) or neutral (18/50), with operating companies showing divergent trends: explosive revenue growth in solar (FTC Solar +110.5% YoY) and AI/hardware (Blaize +2,387% YoY) contrasted by widening net losses in biotechs (e.g., COMPASS +85.6%, Fractyl +105%, Neurogene +20.2%) and sharp declines in energy trusts (VOC -37% income, MV Oil -39%). Retail outliers like GameStop delivered +218.7% net income surge despite -5.1% sales drop via margin expansion (+7.4 pts to 33%), while 25+ ABS/mortgage trusts reported routine Reg AB compliance with no material issues, signaling stable structured finance servicing. Portfolio-level trends reveal biotech cash burn averaging +30% YoY (e.g., Achieve +37%, Neurogene +9.4%), energy reserve/production declines (4-11% YoY), and modest infra growth (Core & Main +2.8% sales). Capital allocation leans toward financing inflows for cash preservation (e.g., FTC +$40.4M), but no broad insider patterns noted; implications favor selective longs in margin improvers amid biotech/energy caution, with ABS neutrality supporting fixed-income stability.

50 high priority50 total filings
·daily

US Earnings Financial Results SEC Filings — March 23, 2026

Across 50 US SEC filings for FY2025 (ended Dec 31, 2025), sentiment is predominantly mixed (28/50), with neutral ABS trusts (12/50) and negative outliers in consumer/hospitality sectors; revenue trends show sharp declines in consumer goods (avg -30% YoY for Aterian, Solo Brands) offset by growth in mining/biotech (e.g., Idaho Strategic +64.6% YoY, Arbutus +128% YoY). Net losses widened in 18 companies (avg +45% YoY in biotechs like Cabaletta, Surrozen), but narrowed in 12 (e.g., Xilio -40%, Sutro -16%); cash positions improved in 15 firms via financing/IPOs, but burned in biotech heavy-hitters. SPACs (Cartesian, SilverBox, Bold Eagle, TGE) reported strong trust interest income (+300-400% YoY) amid negative equity, signaling de-SPAC catalysts. Capital allocation leaned toward debt reduction (Core Labs -13% net debt, Ultralife -12%) over dividends/buybacks; insider activity limited to 10b5-1 selling plans (Avalo, Pyxis) indicating caution. Portfolio-level: Biotech R&D surges (+30-180% YoY) drive losses but fuel pipelines; consumer margin resilience amid sales drops offers turnaround potential; ABS compliance uniform/neutral implies stable securitizations.

50 high priority50 total filings
·daily

US Earnings Financial Results SEC Filings — March 20, 2026

Across 50 10-K and 10-Q filings from March 20, 2026, primarily FY2025 results, a dominant mixed sentiment prevails with 70% of named companies showing revenue growth averaging 40% YoY in high-growth sectors like aerospace (Firefly +163%), tech (Snowflake +29%, Aeva +99%), and retail (Dollar General +5.2%, Victoria's Secret +5%) but persistent net losses widening in 60% of cases due to high opEx/R&D and impairments. SPACs (e.g., Pelican, Bluerock, Jackson) represent ~20% of filings, holding intact trust accounts with interest income driving modest profits amid pre-merger deficits. BDC/investment vehicles (11 filings) expanded assets/portfolios 50-80% YoY with investment income up 50-110%, though yields compressed 100bps to 9.1% on average, signaling rate sensitivity. ABS servicing compliance in 15+ unknown filings remains routine/neutral with no deficiencies, focusing on standard timeframes (2-90 days). Capital allocation leans toward financing inflows ($100M+ in Aeva, Firefly) over dividends/buybacks, with outliers like AutoZone's $742M buybacks. Portfolio-level trends highlight growth resilience but profitability challenges, implying near-term catalysts from guidance-embedded EBITDA targets (Wellgistics to 2026) and product launches (Milestone PSVT in 2026).

50 high priority50 total filings
·daily

US Earnings Financial Results SEC Filings — March 19, 2026

Across 50 filings dominated by neutral ABS servicing compliance disclosures (30+ filings, materiality 3-5/10), key financial reporters show mixed FY2025/Q2 FY2026 results with standout revenue accelerations in tech/memory (Micron +196% YoY Q2 rev to $23.9B) and retail (Ollie's +16.6% sales to $2.65B), offset by declines in health services (DarioHealth -17% rev) and hospitality SSS (ONE Group -3.7%). Aggregate trends reveal 12/20 high-materiality firms with revenue growth averaging +35% YoY (led by Rubrik +48%, Tigo Energy +91.7%), but margins mixed with expansions in 6 (e.g., Micron gross to $17.8B) vs compressions in 7 (avg -150bps where noted); net losses narrowed in 8 biotechs/small caps (e.g., Mustang Bio -88% YoY). Cash positions strengthened in 10 firms (avg +40% YoY, e.g., FedEx to $8B), but deteriorated in 7 (e.g., Lithium Americas liabilities +900%). SPACs (Artius II, Rice) standard pre-deal with trust growth but deficits. No widespread insider activity reported; capital allocation leans reinvestment over returns amid growth focus. Implications: Bullish tech/retail momentum, biotech turnaround watch, ABS stability signal.

50 high priority50 total filings
·daily

US Earnings Financial Results SEC Filings — March 18, 2026

Across 50 10-K and 10-Q filings for FY2025 (mostly ended Dec 31, 2025, filed Mar 18, 2026), dominant mixed sentiment prevails in 70% of detailed reports, with revenue growth in 18/25 quantifiable companies averaging +72% YoY (skewed by outliers like Energy Vault +341%, ProKidney +1,075%, TSS +66%), but offset by widespread margin compression (e.g., 9/15 cases -100bps+), persistent net losses (12/25 widening or flat), and yield declines in investment vehicles (e.g., Unknown #1 9.9% from 11.2%, PGIM 9.88% from 11.11%). Retailers like Home Depot (+3.2% sales) and Best Buy (+0.4%) show resilience via comp sales stability but earnings pressure from costs/stores cuts; tech/AI firms (TSS, Energy Vault, ONE STOP) drive outsized growth amid capex; biotechs (Heartflow +40%, 4DMT +huge via licenses) narrow losses post-IPO/financing but burn cash. Capital allocation leans to financings/debt (e.g., Bob's $337M new LT debt, Accelerant $1.38B distributions causing loss swing), sparse buybacks (TSS minor repurchase); ABS servicing filers (12/50) uniformly neutral/low materiality with no deficiencies. Portfolio implication: Favor high-growth tech/biotech turnarounds over flat retail/banks amid yield headwinds; watch Q1'26 catalysts for guidance.

50 high priority50 total filings
·daily

US Earnings Financial Results SEC Filings — March 17, 2026

Across 50 SEC filings for Q4 2025/FY2025 financial results filed March 17, 2026, sentiment is predominantly mixed (25+ filings) with neutral ABS servicing compliance dominating low-materiality disclosures (15+ filings), signaling routine stability in asset-backed securities servicing but no major issues. Revenue growth trends are uneven: strong outperformers like Ethos Technologies (+52% YoY to $387.6M), Xerox (+12.9% to $7.0B), and HealthEquity (+9% to $1.31B) contrast with decliners like NextNav (-19.3%), IZEA (-13%), and Gossamer Bio (-58%), averaging modest portfolio-level growth of ~15% YoY among high-materiality names. Margin compression is widespread (e.g., Xerox gross margin -440bps to 27.1%, Academy SG&A +820bps to 26.3%), offset by loss narrowing in biotechs (Monte Rosa -47% to $38.6M loss, AN2 -31% to $35.2M) and banks (Mechanics +817% net income post-merger). Capital allocation leans conservative with dividends up in Value Line (+8% nine-month payout to $9.2M) but dilution rampant via equity raises (X4 shares +1495% to 90.9M, Oklo cash +712% to $788M). SPACs like M3-Brigade and ProCap show passive interest income gains ($4.15M, $5.66M) amid no business combinations. Biotech/pharma heavy (12 filings) highlights R&D spend persistence despite cuts, while banking/mining exhibit asset expansion but yield pressures; actionable theme is selective rotation to revenue accelerators like DTC/tech amid macro caution.

50 high priority50 total filings
·daily

US Earnings Financial Results SEC Filings — March 16, 2026

Across 50 US SEC filings for Q4 2025/FY2025 earnings (filed ~March 16, 2026), mixed sentiment prevails in 80% of cases, with biotechs/pharmas (20+ firms) showing widened net losses averaging +30% YoY from R&D spikes but offset by $200M+ aggregate equity raises (e.g., Olema $205M, Zenas via licenses); banks (PCB, Orange County, Embassy) delivered +45% avg net income growth on NIM expansion to ~4% but NPAs rose 50-70% YoY signaling credit stress. Tech/software leaders like Samsara (+30% rev, 77% margins), Dell (+19% rev, $11B op cash flow), Figure (+49% rev) drove positive outliers vs sector drags (LivePerson -22% rev); energy firms mixed with NGS rentals +14% horsepower but Aemetis volumes -7-72%. Portfolio trends: Revenue +10% avg in top 20 performers, cost cuts yielded EBITDA gains in 65% (avg +50%), but cash burns persist in pre-revenue (Eve $224M loss); capital returns via bank dividends (+11% yields) and Dell $1B+ buybacks. Critical: Rising impairments/debt in 40%, but 15 firms flipped to EBITDA positive, implying turnaround alpha in cost-disciplined growth names amid macro caution.

50 high priority50 total filings
·daily

US Earnings Financial Results SEC Filings — March 13, 2026

Across 50 10-K and 10-Q filings from March 13, 2026, primarily US banks, financial services, investment vehicles, and select industrials/biotechs, overarching themes include resilient balance sheet growth in banking (avg assets +5% YoY across 20+ cos, loans +7% avg) with NIM expansions in 15/20 banks (avg +25bps YoY) but offset by rising provisions/NPAs in 8 cos. Non-bank financials and BDCs show strong portfolio ramps (e.g., investments +37% to 84 cos in one, net assets +132% in another) and revenue growth in outliers like Jefferson Capital (+42% revenues), while industrials/manufacturing face revenue declines (avg -8% YoY in 7 cos) amid margin compression. Capital allocation leans shareholder-friendly with buybacks/dividends in 12 cos (e.g., First Northern 1M+ shares thru Apr 2026, multiple dividend hikes), but mixed sentiment dominates (45/50 mixed/negative) signals caution on profitability deterioration (ROA/ROE down in 10 cos). Forward-looking catalysts include merger integrations (Esquire/Signature), patent risks (Vaxart Inavir 2036), and buyback/stock dividend dates. Portfolio-level: Banks outperform on NIM/ROE vs non-financials' EBITDA declines (avg -15% in 10 cos), highlighting defensive rotation into regional banks with strong capital returns amid deposit growth (+6% avg). Critical implication: Opportunities in outperforming banks (e.g., Red River ROE 12.6%) vs risks in provision-heavy lenders.

50 high priority50 total filings
·daily

US Earnings Financial Results SEC Filings — March 12, 2026

Across 50 US SEC filings for Q4/FY2025 financial results (filed March 12, 2026), sentiment is predominantly mixed (38/50), with only 3 positive and 5 negative, reflecting resilient revenue growth in select financials (e.g., Orrstown NII +28.7% YoY, Sonida resident revenue +23.9%) offset by declines in consumer/retail (Bath & Body Works -0.2%, Funko -13.5%) and dramatic swings in crypto trusts (inflows strong but NAV down 15-40% on asset depreciation). Period-over-period trends show average revenue growth of ~8% YoY where positive, but margin compression in 15 companies (avg -100bps), widening net losses in biotechs/pharma despite cost cuts, and robust balance sheet expansion in banks (avg assets +15%). Crypto ETFs/trusts (10 filings) highlight massive inflows ($100M+ in several) amid unrealized losses, signaling volatility plays. Financial health varies: cash surges in 20 firms (e.g., National Beverage +62%), but impairments and debt concerns flag risks in 12. Portfolio-level implications favor overweighting regional banks with NIM gains and monitoring crypto ETF catalysts, while underweighting retail amid occupancy/ sales softness.

50 high priority50 total filings
·daily

US Earnings Financial Results SEC Filings — March 11, 2026

Across the 50 filings in the Financial Results & Earnings stream (46 new), results are predominantly mixed with 22 positive, 15 negative, and 13 neutral sentiments, reflecting resilient growth in cloud/tech (e.g., Oracle +22% YoY revenue to $17.2B, Marvell +42% to $8.2B) and retail giants (Costco +9.3% Q2 revenue to $69.6B) offset by sharp declines in AI/software (C3.ai -46% Q3 revenue to $53.3M) and consumer staples (Campbell's -4.5%, Target -1.7% FY sales). Period-over-period trends show average revenue growth of +15% YoY in top performers (n=18) but -10% in laggards (n=12), with margin compression averaging -100bps in 14 companies due to higher OpEx/R&D; banks expanded assets +30% avg (n=5) but NIM mixed (improving in CNB/LCNB, declining elsewhere). Biotechs/pharmas (n=12) narrowed net losses 20-77% via cost cuts, while SPACs (n=4) saw trust redemptions -70-92%. Capital allocation favors dividends/buybacks in stables (Costco EPS +14%, Oil-Dri dividends +24%), acquisitions drive growth (AeroVironment +143% revenue). Portfolio implications: overweight tech/cloud/defense outperformers, underweight high-burn AI/biotechs; watch bank NIM and biotech cash burns for Q1 2026 catalysts amid 2026-03 period focus.

50 high priority50 total filings
·daily

US Earnings Financial Results SEC Filings — March 10, 2026

Across 50 US SEC filings for Q4 2025 and FY2025 earnings, overarching themes include mixed financial performance with 28/50 companies showing revenue growth (avg +12% YoY where reported) offset by widespread operating losses and margin compression (avg -150bps in 15/22 detailed cases), particularly in biotechs and cyclicals. Biotech firms (e.g., Q32 Bio, Rapport) reported collaboration revenue boosts but R&D surges widening losses 20-50% YoY, while service/revenue growers like TWFG (+22% rev, +44% NI) and Evolv (+40% rev, EBITDA positive swing) stood out. SPACs faced heavy redemptions and trust declines (Trailblazer assets -84%), energy/mining mixed (Uranium Energy profit swing), and real estate/REITs saw portfolio contractions. Capital allocation leaned toward financing raises over buybacks/dividends (only 4 cases), with cash burn persistent in 22/50 but improving FCF in 10. Portfolio-level: Net losses in 32/50, but 18 showed loss narrowing or profit swings; implications point to selective opportunities in high-growth niches amid macro caution, with no major guidance changes but risks from impairments/delisting.

50 high priority50 total filings
← All geographies